FDA-approved medications targeting neurological conditions discussed alongside investment opportunities for companies like Supernus, Datadog, and Coinbase.
1 report, 1 independent
Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA-approved medications targeting neurological conditions discussed alongside investment opportunities for companies like Supernus, Datadog, and Coinbase.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
- FDA
Related events
- Shares of Scholar Rock Holding Corporation were traded on the Nasdaq exchange while the FDA approved ISEMBYLD for spinal muscular atrophy.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- The FDA recommended advancement for a new drug application submitted by a company.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
Coverage
Newest first; wire copies grouped- StockStory2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business